Our agile research team has miles of experience.
Experts in antigen design and hybridoma development.
In-depth experience from gene synthesis and subcloning to protein expression and purification.
Proven track record for a broad range of in vitro and in vivo models of disease.
Short timelines and high titers at every development stage with RapTr™ CLD services.
Aragen’s RapTr™ Cell Line Development services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process that delivers high titers at every stage from Discovery to the Clinic.
Idiopathic Pulmonary Fibrosis Summit
August 21-23, 2017 | Boston, MA
August 21-24, 2017 | Boston, MA
Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189
Lung Therapeutics Announces Series B Funding
…a solid performer for my company’s animal studies…
Elisabeth Gardiner, PhD Chief Scientific Officer Meditope Biosciences, Inc.
RapTr Cell Line Development services introduced
New president appointed